Patent
Drug preparation comprising α-lipoic acid, ambroxol and/or inhibitors of the angiotensin-converting enzyme (ACE) and its use for the treatment of neurodegenerative diseases
| العنوان: | Drug preparation comprising α-lipoic acid, ambroxol and/or inhibitors of the angiotensin-converting enzyme (ACE) and its use for the treatment of neurodegenerative diseases |
|---|---|
| Patent Number: | 7,858,655 |
| تاريخ النشر: | December 28, 2010 |
| Appl. No: | 10/764676 |
| Application Filed: | January 26, 2004 |
| مستخلص: | The present invention concerns the use of Provided is a drug composition and a method for using the composition for the prevention and the therapy of neurodegenerative diseases. The combination comprises at least two of the following substances: α-lipoic acid; ambroxol and one or several inhibitor(s) of the angiotension-converting enzyme (ACE). |
| Inventors: | Röhnert, Peter (Magdeburg, DE); Striggow, Frank (Gerwisch, DE); Reymann, Klaus (Niederndodeleben, DE); Ansorge, Siegfried (Hohenwarte, DE); Täger, Michael (Heinrichsberg, DE); Schröder, Ulrich (Eussenheim, DE) |
| Assignees: | Keyneurotek Pharmaceuticals AG (Magdeburg, DE) |
| Claim: | 1. A method for therapy of a neurodegenerative disease or ischemia comprising administering to an individual an effective amount of a composition comprising ambroxol or its salts and at least one inhibitor of the angiotension-converting enzyme, wherein the therapy of the neurodegenerative disease or ischemia comprises a synergistic inhibition of neuronal damage. |
| Claim: | 2. The method according to claim 1 , wherein the neurodegenerative disease is selected from the group consisting of ischemic or hemorrhagic stroke, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Hunntington's disease, multiple sclerosis, neurodegeneration of aged people, dementia, cranial cerebral trauma, and Autosomal Dominant Neurohypophyseal Diabetes Insipidus. |
| Claim: | 3. The method of claim 1 , wherein the ischemia is cerebral ischemia resulting from cardiac and cardiovascular insults. |
| Claim: | 4. The method of claim 1 , wherein the composition further comprises α-lipoic acid or its salts or its isomers. |
| Claim: | 5. The method of claim 1 , wherein the composition further comprises pharmaceutically acceptable carriers, additives and/or adjuvants. |
| Claim: | 6. The method of claim 4 , wherein the α-lipoic acid or its salts or its isomers are administered in an amounts of from 30 to 1,200 mg/day, and/or ambroxol or its salts are administered in an amount of from 7.5 to 90 mg/day, and/or at the inhibitor of the angiotensin-converting enzyme is administered in an amount of from 1 to 50 mg/day. |
| Claim: | 7. The method of claim 6 , wherein the α-lipoic acid or its salts or its isomers are administered in an amounts of from 200 to 600 mg/day, and/or ambroxol or its salts are administered in an amount of from 60 to 75 mg/day, and/or at the inhibitor of the angiotensin-converting enzyme is administered in an amount of from 5 to 20 mg/day. |
| Claim: | 8. The method of claim 1 , wherein the composition is administered by a route selected from buccal, pulmonal, nasal, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal and intrathecal administration. |
| Claim: | 9. The method of claim 1 , wherein the composition is administered in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents. |
| Claim: | 10. A composition comprising ambroxol or its salts and at least one inhibitor of the angiotension-converting enzyme, wherein the composition is capable of synergistically inhibiting neuronal damage. |
| Claim: | 11. A method for obtaining a synergistic improvement in the survival of neuronal cells after oxygen and/or glucose deprivation in an individual comprising administering to the individual a composition comprising ambroxol, at least one inhibitor of the angiotensin-converting enzyme, and α-lipoic acid. |
| Claim: | 12. The method of claim 11 , wherein the inhibitor of the angiotensin-converting enzyme is selected from the group consisting of captopril, lisinopril, enalapril, ramipril, spirapril, imidapril and moexipril. |
| Claim: | 13. The method of claim 12 , wherein the angiotensin-converting enzyme is elanapril. |
| Claim: | 14. The method of claim 11 , wherein the composition further comprises a pharmaceutically acceptable carrier. |
| Current U.S. Class: | 514/412 |
| Patent References Cited: | 2002/0177558 November 2002 Meyerhoff et al. WO 02/096398 December 2002 WO 02/096414 December 2002 |
| Other References: | Gillissen et al., Respiratory Med. (1998), vol. 92, pp. 609-623. cited by examiner Derick et al., Biochem. Biophy. Research Comm. (1995), vol. 207, No. 1, pp. 258-264. cited by examiner Elena et al., Am. J. Physiol. Regulatory Integrative Comp. Physiol., (2000), vol. 278, pp. R572-R577. cited by examiner Biewenga et al., Gen, Pharm, (1997), vol. 29(3), pp. 315-331. cited by examiner Jablonka, Stanislaw, Andrzej Ledwozyw, Wojciech Kadziolka, Andrzej Jablonka, and Andrzej Nestorowicz, “The Influence Of Ambroxol On Peroxidative Processes In Lung And Plasma In Dogs After Pulmonectomy,” Archivum Veterinarium Polonicum, 1992, pp. 57-66, vol. 32, No. 1-2. cited by other Kozhevnikova, E.V. and L.M. Adzhienko, “Neuroprotective Activity Of Angiotensin-Converting Enzyme Inhibitors In Cerebral Ischemia,” Bulletin Of Experimental Biology And Medicine, 1999, pp. 1122-1124, vol. 11. cited by other Packer, Lester, Hans J. Tritschler, and Klaus Wessel, “Neuroprotection By The Metabolic Antioxidant α-Lipoic Acid,” Free Radical Biology & Medicine, 1997, pp. 359-378, vol. 22, No. ½. cited by other Ravati, Alexander, Vera Junker, Maria Kouklei, Barbara Ahlemeyer, Carsten Culmsee, and Josef Krieglstein, “Enalapril And Moexipril Protect From Free Radical-Induced Neuronal Damage In Vitro And Reduce Ischemic Brain Injury In Mice And Rats,” European Journal Of Pharmacology, 1999, pp. 21-33, vol. 373. cited by other Stoll, S., A. Rostock, R. Bartsch, E. Korn, A. Meichelböock, and W.E. Müller, “The Potent Free Radical Scavenger α-Lipoic Acid Improves Cognition In Rodents,” Annals New York Academy Of Sciences, 1994, pp. 122-128. cited by other Werner, Christian, William E. Hoffman, Eberhard Kochs, Sara F. Rabito, and David J. Miletich, “Captopril Improves Neurologic Outcome From Incomplete Cerebral Ischemia In Rats,” Stroke, Jul. 1991, pp. 910-914, vol. 22, No. 7. cited by other |
| Primary Examiner: | Solola, Taofiq A |
| Attorney, Agent or Firm: | Hodgson Russ LLP |
| رقم الانضمام: | edspgr.07858655 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |